Answers are grounded in this paper and cite their sources.
Objectives The Mayo 2012 and European‐modified Mayo 2004 (European‐modified) staging systems are widely used in systemic light‐chain (AL) amyloidosis, but their comparative prognostic performance in patients with discordant stage classifications remains unclear. Methods We retrospectively analyzed 177 patients with systemic AL amyloidosis treated with first‐line bortezomib‐based therapy between January 2020 and March 2025. Patients were classified using both staging systems, and discordance was assessed using predefined stage mapping. Overall survival (OS) was evaluated using Kaplan–Meier analysis, time‐dependent receiver operating characteristic curves, concordance indices, and Cox regression. Hematologic and organ responses were assessed as exploratory outcomes. Results Discordant stage classifications were identified in 83 patients (46.9%). In this subgroup, the European‐modified system demonstrated significant separation of OS curves across stages (log‐rank p = 0.0008), identifying Stage IIIB as a particularly high‐risk group with a median OS of 2.9 months. The Mayo 2012 system also significantly stratified OS. At 6 months, the European‐modified system showed a numerically higher time‐dependent AUC than the Mayo 2012 system (0.759 vs. 0.614), although the difference was not statistically significant ( p = 0.092). Similar nonsignificant differences were observed at 12 and 24 months, and differences in Harrell's and Uno's C‐indices were also not statistically significant. Exploratory treatment response analyses were limited by potential selection bias and nonuniform response assessment. Conclusions Among patients with discordant stage classifications, the European‐modified system demonstrated significant OS stratification and identified patients at particularly high risk of early mortality. Although it showed numerically higher prognostic discrimination than the Mayo 2012 system, the differences were not statistically significant. These findings suggest potential clinical utility for early risk stratification but require validation in larger independent cohorts.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: